We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ingrid
Emmerson
i.emmerson@nhs.net
Prof
Colin
Rees
colin.rees@newcastle.ac.uk
Ingrid
Emmerson
ingrid.emmerson@stft.nhs.uk
Amy
Burns
amy.burns6@nhs.net
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Bowel cancer is the second commonest cause of cancer death in the UK with 16000 people dying per year. Although the NHS Bowel Cancer Screening Programme (BCSP) detects cancers at an earlier stage only 10% of all cancers are detected through screening.
Currently, the only criteria for screening is age and no account is taken of other known risk factors such as smoking, alcohol, family history or obesity. Stool FIT (a new stool test which detects blood that can’t be seen with the naked eye) will be introduced into the English BCSP, but there is poor evidence for its use in patients presenting with symptoms. There are emerging data that there may be differences in the gut bacteria of people with and without cancer or pre cancerous bowel polyps (adenomas).
This will be a national multi-centre study over 5-years. 10000 Patients undergoing colonoscopy as part of BCSP or due to symptoms will be recruited. They will be asked to fill in a health questionnaire, have their height, weight, waist circumference measured. They will also receive blood tests, stool tests or saliva tests depending on the indication for their colonoscopy. The results of the colonoscopy and any samples taken will be collated. Patients will receive a patient experience questionnaire or food frequency questionnaire. 10000 patients from the North of England will also be consented to be contacted for future studies with some of the information above collected.
Our aim is to develop a risk model to help determine which patients are at highest risk of having adenomas or bowel cancer. We will also explore the significance of the gut bacteria composition in patients with adenomas or cancer to help inform this risk model. Additionally we will develop a large platform of patients who consent to be contacted for future research.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Group A Unable to give informed consent Known polyposis syndrome Previous total colectomy Known colonic stricture which would limit complete colonoscopy Attending for planned therapeutic procedure other than polypectomy, such as insertion of colonic stent Attending for assessment of known inflammatory bowel disease (IBD) activity or for IBD surveillance Patients currently recruited into an interventional CTIMP for CRC prevention* COLO-SPEED (Group B) ** Unable to give informed consent Not in a centre supported by COLO-SPEED infrastructure (i.e. not in the North of England) *Patients recruited to COLO-COHORT Group A are not excluded from participation in other research studies other than chemoprevention studies. ** COLO-SPEED (Group B) aims to establish a consent for contact database guiding patients into other studies therefore inclusion in other studies is desirable therefore all patients are eligible for group B Withdrawal Criteria Withdrawal of consent from study participation Withdrawal of consent for colonoscopy pre procedure
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ingrid
Emmerson
i.emmerson@nhs.net
Prof
Colin
Rees
colin.rees@newcastle.ac.uk
Ingrid
Emmerson
ingrid.emmerson@stft.nhs.uk
Amy
Burns
amy.burns6@nhs.net
The study is sponsored by SOUTH TYNESIDE AND SUNDERLAND NHS FOUNDATION TRUST and funded by GUTS UK CHARITY .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 42483
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
